No Data
No Data
Pfizer Raises Outlook Amid Strong Demand for Non-Covid Products -- WSJ
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $32 to $45
Wall Street's Great Rotation Ushers Out Tech in Favor of New Sectors
Express News | Viiv Healthcare Announces Positive Data Demonstrating 2-Drug Regimen Dovato Is as Effective as 3-Drug Regimen Biktarvy for Maintenance Therapy of Hiv-1
Telescope Innovations and Pfizer Sign Master Collaborative Research Agreement
Cantor Fitzgerald Sticks to Its Buy Rating for Pfizer (PFE)